GSA Capital Partners LLP acquired a new stake in shares of InfuSystem Holdings, Inc. (NYSE:INFU - Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 160,439 shares of the company's stock, valued at approximately $1,548,000. GSA Capital Partners LLP owned about 0.79% of InfuSystem as of its most recent filing with the SEC.
Other institutional investors have also modified their holdings of the company. Quarry LP purchased a new position in InfuSystem during the fourth quarter valued at approximately $31,000. Raymond James Financial Inc. purchased a new stake in InfuSystem in the 2nd quarter worth approximately $33,000. Virtu Financial LLC acquired a new stake in shares of InfuSystem during the 4th quarter worth approximately $90,000. LPL Financial LLC acquired a new stake in shares of InfuSystem during the 4th quarter worth approximately $92,000. Finally, Jane Street Group LLC purchased a new position in shares of InfuSystem during the 1st quarter valued at approximately $96,000. Hedge funds and other institutional investors own 71.13% of the company's stock.
InfuSystem Price Performance
NYSE INFU opened at $12.27 on Monday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.59 and a current ratio of 1.98. The business has a fifty day moving average price of $9.86 and a 200 day moving average price of $9.39. The company has a market cap of $247.63 million, a P/E ratio of 204.53 and a beta of 1.42. InfuSystem Holdings, Inc. has a one year low of $7.29 and a one year high of $12.97.
InfuSystem declared that its Board of Directors has authorized a stock repurchase program on Tuesday, May 19th that allows the company to repurchase $20.00 million in shares. This repurchase authorization allows the company to repurchase up to 10.2% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company's board believes its stock is undervalued.
Analyst Upgrades and Downgrades
Separately, B. Riley Financial reiterated a "buy" rating and issued a $20.00 target price (up from $12.00) on shares of InfuSystem in a research note on Wednesday, August 5th. Three investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat, InfuSystem presently has a consensus rating of "Moderate Buy" and an average price target of $16.67.
Get Our Latest Stock Analysis on InfuSystem
About InfuSystem
(
Free Report)
InfuSystem Holdings Inc is a medical technology company that specializes in the rental, management and servicing of infusion pumps and associated devices used primarily for outpatient infusion therapy. The company provides a comprehensive suite of services that includes equipment delivery, setup and retrieval, preventive and corrective maintenance, reprocessing and quality assurance. InfuSystem's offerings are designed to help hospitals, ambulatory surgery centers, oncology clinics and private infusion suites streamline clinical operations and maintain compliance with safety standards.
In addition to pump rental and repair services, InfuSystem has expanded into remote patient monitoring solutions.
See Also
Want to see what other hedge funds are holding INFU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for InfuSystem Holdings, Inc. (NYSE:INFU - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider InfuSystem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InfuSystem wasn't on the list.
While InfuSystem currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.